Lingjuan Chen
Overview
Explore the profile of Lingjuan Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
274
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dong J, Chen L, Feng Q, Yang D
Angew Chem Int Ed Engl
. 2024 Oct;
64(5):e202417200.
PMID: 39363682
A novel design strategy to construct bright and narrow near-infrared (NIR) emission materials with suppressed shoulder peaks can significantly enhance their performance in various applications. Herein, we have successfully synthesized...
2.
Jiang J, Li X, Wang J, Chen S, Chen L
Cancer Med
. 2024 Sep;
13(18):e70253.
PMID: 39344563
Background: Investigating the molecular mechanism of colorectal cancer (CRC), a common lethal malignancies worldwide, is of great clinical significance. Solute carrier family 25 member 19 (SLC25A19) is a member of...
3.
Chen L, Kong Y, Tong F, Zhang R, Ding P, Zhang S, et al.
Chin Med J (Engl)
. 2024 Sep;
PMID: 39307928
Background: The purpose of this study was to evaluate the safety and efficacy of subsequent radiotherapy (RT) following first-line treatment with durvalumab plus chemotherapy in patients with extensive-stage small cell...
4.
Liu L, Wang J, Wang Y, Chen L, Peng L, Bin Y, et al.
J Exp Clin Cancer Res
. 2024 Apr;
43(1):128.
PMID: 38685050
Background: Brain metastasis is one of the main causes of recurrence and death in non-small cell lung cancer (NSCLC). Although radiotherapy is the main local therapy for brain metastasis, it...
5.
Tian S, Chen L, Wang X, Li G, Fu Z, Ji Y, et al.
Cortex
. 2024 Apr;
174:241-255.
PMID: 38582629
Shape is a property that could be perceived by vision and touch, and is classically considered to be supramodal. While there is mounting evidence for the shared cognitive and neural...
6.
Ye J, Chen L, Waltermire J, Zhao J, Ren J, Guo Z, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473379
The success of cancer immunotherapy is largely associated with immunologically hot tumors. Approaches that promote the infiltration of immune cells into tumor beds are urgently needed to transform cold tumors...
7.
Chen L, Zuo M, Zhou Q, Wang Y
Front Immunol
. 2024 Jan;
14:1308890.
PMID: 38169820
Oncolytic viruses (OVs) are emerging cancer therapeutics that offer a multifaceted therapeutic platform for the benefits of replicating and lysing tumor cells, being engineered to express transgenes, modulating the tumor...
8.
Peng L, Bin Y, Ding P, Chen L, Zeng H, Xu Z, et al.
Cancer Commun (Lond)
. 2023 Feb;
43(5):625-629.
PMID: 36815673
No abstract available.
9.
Chen L, Zhang R, Lin Z, Tan Q, Huang Z, Liang B
Front Immunol
. 2023 Feb;
14:1100079.
PMID: 36742293
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment in recent years and provide new opportunities to treat hepatocellular carcinoma (HCC). To date, several ICIs have been approved by the FDA...
10.
Tan Q, Liu L, Huang Y, Dong X, Chen L
Front Oncol
. 2022 Dec;
12:973421.
PMID: 36505877
Background: Immune checkpoint inhibitors, including anti-PD-1 therapies, have prolonged overall survival in patients with a variety of cancers, and immunotherapy is sometimes associated with immune-related adverse events (irAEs); however, hematological...